D. Boral Capital Reiterates "Buy" Rating for Cytosorbents (NASDAQ:CTSO)

Key Points

• Cytosorbents' stock has been restated with a "buy" rating by D. Boral Capital, with a price target of $10.00.
• The company reported a quarterly EPS of ($0.05), exceeding expectations, while revenue was slightly below consensus at $9.62 million.
• Cytosorbents has seen significant institutional investment, with various hedge funds raising their stakes in recent quarters, indicating increasing confidence in the company's prospects.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the medical research company's stock.

Separately, Wall Street Zen began coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They set a "hold" rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Cytosorbents Trading Up 0.9%

CTSO traded up $0.01 during trading on Tuesday, hitting $0.94. 122,945 shares of the company's stock were exchanged, compared to its average volume of 84,068. The company has a current ratio of 2.34, a quick ratio of 1.96 and a debt-to-equity ratio of 1.24. Cytosorbents has a 1 year low of $0.71 and a 1 year high of $1.61. The stock has a 50 day moving average price of $0.97 and a 200 day moving average price of $1.00. The firm has a market cap of $59.06 million, a P/E ratio of -5.54 and a beta of 1.28.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. The business had revenue of $9.62 million for the quarter, compared to analysts' expectations of $9.79 million. As a group, analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Trading of Cytosorbents

A number of institutional investors and hedge funds have recently modified their holdings of the business. Avenir Corp raised its holdings in shares of Cytosorbents by 0.3% during the second quarter. Avenir Corp now owns 5,058,537 shares of the medical research company's stock worth $6,475,000 after purchasing an additional 13,619 shares during the period. Northern Trust Corp raised its holdings in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after purchasing an additional 16,701 shares during the period. Millennium Management LLC acquired a new stake in shares of Cytosorbents during the fourth quarter worth $30,000. Goldman Sachs Group Inc. raised its holdings in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after purchasing an additional 37,519 shares during the period. Finally, Key Client Fiduciary Advisors LLC raised its holdings in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after purchasing an additional 43,900 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.